Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Immune Checkpoint Inhibition Among Patients With Dermatologic and Hematologic Cancers

By: Lauren Harrison, MS
Posted: Wednesday, December 2, 2020

Immune checkpoint inhibitors appear to be efficacious in patients with skin cancer who have a concurrent hematologic malignancy; however, the effect seemed to be impaired among patients with cutaneous squamous cell carcinoma but not with metastatic melanoma or Merkel cell carcinoma. Selma Ugurel, MD, of the University of Duisburg-Essen, Germany, and her colleagues published this study in the Journal for ImmunoTherapy of Cancer.

This retrospective, multicenter study included 84 patients with metastatic melanoma (n = 52), cutaneous squamous cell carcinoma (n = 15), or Merkel cell carcinoma (n = 17) who had a previous hematologic malignancy diagnosis (70 with non-Hodgkin lymphoma and 32 with chronic lymphocytic leukemia). A control group without a hematologic malignancy was identified from the prospective multicenter skin cancer registry ADOREG.

Among this cohort, 9 received immunotherapy in an adjuvant setting, whereas 75 were treated for advanced nonresectable malignancies. Patients were treated with anti–PD-1 therapy (n = 55), anti–PD-L1 therapy (n = 8), anticytotoxic T-lymphocyte–associated protein 4 therapy (n = 5), or a combination regimen (n = 7) for their primary skin malignancies. Within the group of patients treated for nonresectable tumors, the best objective response (complete response plus partial response) was 28.0%, and disease stabilization was 25.3%. Progressive disease was noted among 38.6% of patients. The best objective response was seen among patients with metastatic melanoma (31.1%), whereas those with cutaneous squamous cell and Merkel cell carcinomas had an objective response of 26.7% and 18.8%, respectively. The median progression-free survival was 8.4 months, 4.0 months, and 5.7 months among patients with melanoma, squamous cell carcinoma, and Merkel cell carcinoma, respectively.

In comparison to the 392 patients without a hematologic malignancy, there was no difference in immunotherapy outcomes for patients with Merkel cell carcinoma or malignant melanoma. However, those with squamous cell carcinoma had a significantly reduced progression-free survival when compared with counterparts without hematologic malignancies (P = .002).

Disclosure: For a full list of authors’ disclosures, visit jitc.bmj.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.